Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Completed · Phase 1
Conditions studied: Lymphoma, Small Intestine Cancer
In brief
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat after stem cell transplant in treating patients with high-risk lymphoma.
Key facts
- Study ID
- NCT00561418
- Run by
- Ohio State University Comprehensive Cancer Center
- People needed
- 23
- Starts
- 2007-11-01
- Expected to finish
- 2013-05-01
- Last updated by the study team
- 2015-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ohio State University Medical Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.